% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Laschinsky:285009,
      author       = {C. Laschinsky$^*$ and S. Theurer$^*$ and T. Herold$^*$ and
                      J. Rawitzer$^*$ and F. Weber$^*$ and K. Herrmann$^*$ and T.
                      Brandenburg$^*$ and D. Führer-Sakel$^*$ and W. P.
                      Fendler$^*$ and M. Weber$^*$},
      title        = {{M}olecular {M}arkers {A}re {A}ssociated with {O}nset of
                      {R}adioiodine {R}efractoriness in {P}atients with
                      {P}apillary {T}hyroid {C}arcinoma.},
      journal      = {Journal of nuclear medicine},
      volume       = {64},
      number       = {12},
      issn         = {0097-9058},
      address      = {New York, NY},
      publisher    = {Soc.},
      reportid     = {DKFZ-2023-02182},
      pages        = {1865-1868},
      year         = {2023},
      note         = {2023 Dec 1;64(12):1865-1868},
      abstract     = {The onset of radioiodine-refractory thyroid carcinoma
                      (RR-TC) is a negative predictor of survival and has been
                      linked to the presence of BRAFV600E mutations in papillary
                      thyroid cancer. We aimed to identify further genetic
                      alterations associated with RR-TC. Methods: We included 38
                      patients with papillary thyroid cancer who underwent
                      radioiodine imaging and 18F-FDG PET/CT after total
                      thyroidectomy. The molecular profile was assessed by
                      next-generation sequencing. The time to the onset of RR-TC
                      for different genetic alterations was compared using the
                      log-rank test. Results: The median onset to RR-TC was 0.7
                      and 19.8 mo in patients with and without, respectively,
                      telomerase reverse transcriptase promoter mutations (P =
                      0.02) and 1.7 and 19.8 mo in patients with and without,
                      respectively, a tumor protein 53 mutation (P < 0.01). This
                      association was not observed for BRAFV600E mutations (P =
                      0.49). Conclusion: Our data show a significant association
                      between the onset of RR-TC and mutations in telomerase
                      reverse transcriptase promoter and tumor protein 53,
                      indicating the need for a more extensive diagnostic workup
                      in these patients. Certain genetic changes put patients with
                      thyroid cancer at risk of developing cancer spread that does
                      not respond to radioiodine therapy.},
      keywords     = {TP53 (Other) / molecular alterations (Other) / molecular
                      imaging (Other) / papillary thyroid cancer (Other) /
                      radioiodine refractoriness (Other) / radionuclide therapy
                      (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37884333},
      doi          = {10.2967/jnumed.123.266044},
      url          = {https://inrepo02.dkfz.de/record/285009},
}